Ultragenyx Pharmaceutical Dirección
Dirección controles de criterios 2/4
El CEO de Ultragenyx Pharmaceutical's es Emil Kakkis , nombrado en Apr 2010, tiene una permanencia de 14.17 años. compensación anual total es $13.08M, compuesta por 6.3% salario y 93.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.64% de las acciones de la empresa, por valor de $94.98M. La antigüedad media del equipo directivo y de la junta directiva es de 8.5 años y 8.2 años, respectivamente.
Información clave
Emil Kakkis
Chief Executive Officer (CEO)
US$13.1m
Compensación total
| Porcentaje del salario del CEO | 6.3% |
| Permanencia del CEO | 14.4yrs |
| Participación del CEO | 2.9% |
| Permanencia media de la dirección | 8.7yrs |
| Promedio de permanencia en la Junta Directiva | 8.4yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04
Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
Aug 22There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump
Aug 03Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being
Jun 12Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Jun 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
Mar 09Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise
Dec 28Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?
Sep 12An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued
May 24Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet
Apr 17Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate
Feb 18Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers
Oct 13Ultragenyx grants stock options, restricted stock units
Oct 05Ultragenyx Pharmaceuticals: Downward Trajectory Likely To Continue
Sep 02Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$585m |
| Mar 31 2024 | n/a | n/a | -US$613m |
| Dec 31 2023 | US$13m | US$824k | -US$607m |
| Sep 30 2023 | n/a | n/a | -US$635m |
| Jun 30 2023 | n/a | n/a | -US$721m |
| Mar 31 2023 | n/a | n/a | -US$719m |
| Dec 31 2022 | US$12m | US$796k | -US$707m |
| Sep 30 2022 | n/a | n/a | -US$678m |
| Jun 30 2022 | n/a | n/a | -US$506m |
| Mar 31 2022 | n/a | n/a | -US$470m |
| Dec 31 2021 | US$10m | US$769k | -US$454m |
| Sep 30 2021 | n/a | n/a | -US$356m |
| Jun 30 2021 | n/a | n/a | -US$351m |
| Mar 31 2021 | n/a | n/a | -US$204m |
| Dec 31 2020 | US$5m | US$759k | -US$187m |
| Sep 30 2020 | n/a | n/a | -US$256m |
| Jun 30 2020 | n/a | n/a | -US$301m |
| Mar 31 2020 | n/a | n/a | -US$425m |
| Dec 31 2019 | US$7m | US$714k | -US$403m |
| Sep 30 2019 | n/a | n/a | -US$397m |
| Jun 30 2019 | n/a | n/a | -US$371m |
| Mar 31 2019 | n/a | n/a | -US$325m |
| Dec 31 2018 | US$5m | US$680k | -US$198m |
| Sep 30 2018 | n/a | n/a | -US$192m |
| Jun 30 2018 | n/a | n/a | -US$183m |
| Mar 31 2018 | n/a | n/a | -US$204m |
| Dec 31 2017 | US$7m | US$638k | -US$302m |
Compensación vs. Mercado: La compensación total de Emil($USD13.08M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.83M).
Compensación vs. Ingresos: La compensación de Emil ha aumentado mientras la empresa no es rentable.
CEO
Emil Kakkis (64 yo)
14.4yrs
Permanencia
US$13,077,993
Compensación
Dr. Emil D. Kakkis, M.D., Ph D., is Executive Director of Amlogenyx Inc. Dr. Kakkis has been a Director of Actio Biosciences Inc. since July 2024. He is Venture Advisor of Forge Life Science Partners.He i...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 14.4yrs | US$13.08m | 2.92% $ 146.1m | |
| Executive VP of Corporate Strategy & CFO | less than a year | US$5.94m | sin datos | |
| Chief Legal Officer & Executive VP of Corporate Affairs | 8.3yrs | US$4.04m | 0.017% $ 833.2k | |
| Chief Quality Operations Officer & Executive VP of Translational Sciences | 9.2yrs | US$4.05m | 0.051% $ 2.5m | |
| Executive VP & Chief Commercial Officer | no data | US$4.07m | 0.025% $ 1.2m | |
| Senior VP | 10.7yrs | sin datos | 0.019% $ 968.0k | |
| Chief Human Resources Officer & Executive VP | 4yrs | sin datos | sin datos | |
| Chief Business Officer & Executive VP | 12.8yrs | US$2.46m | 0.23% $ 11.4m | |
| Senior Vice President of Business Development & Alliance Management | 6.5yrs | sin datos | sin datos | |
| Chief Technical Operations Officer and Executive VP of Gene Therapy Research & Development | 9.3yrs | US$4.24m | 0.044% $ 2.2m | |
| Senior Vice President of Corporate Strategy & Finance | no data | sin datos | sin datos | |
| Chief Medical Officer & Executive VP | 1.3yrs | sin datos | 0.020% $ 1.0m |
8.7yrs
Permanencia media
58yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RARE es experimentado (8.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 14.4yrs | US$13.08m | 2.92% $ 146.1m | |
| Independent Non-Executive Chairman | 9.4yrs | US$499.89k | 0.023% $ 1.2m | |
| Independent Director | 10.7yrs | US$479.89k | 0.016% $ 808.6k | |
| Independent Director | 5.6yrs | US$466.89k | 0.016% $ 808.6k | |
| Independent Director | 7.4yrs | US$459.89k | 0.021% $ 1.1m | |
| Independent Director | 3.3yrs | US$469.39k | 0.0058% $ 290.8k | |
| Independent Director | 9.6yrs | US$482.39k | 0.023% $ 1.2m | |
| Independent Director | 2.4yrs | US$460.39k | 0.011% $ 575.5k |
8.4yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de RARE se considera experimentada (8.2 años de antigüedad promedio).